2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.
Vassiliki Papadimitrakopoulou, MD Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial that is exploring MEDI4736, GDC-0032, palbociclib, AZD4547, and rilotumumab in select patients with squamous cell carcinoma of the lung.
In the trial, next-generation sequencing is used to interrogate each tumor sample for multiple alterations, rather than single mutational analysis. The study is then designed to stratify patients to various arms of the program based on each unique molecular subset, giving each patient an opportunity to participate in a clinical trial targeting their exact driver alteration, Papadimitrakopoulou says. If a patient is screened and does not have an alteration, they will be placed in the immunotherapy arm looking at MEDI4736.
The trial features an integrative design that allows patients to transition from the phase II trial to a phase III trial. This provides a more efficient way to get drugs to patients safely and effectively, Papadimitrakopoulou says. The study hopes to speed the discovery of new agents with effective biomarkers for patient with lung cancer. The design of this trial benefits the patients, the academic community and the industry, Papadimitrakopoulou says.